Keros Therapeutics vs Roivant Sciences
KROS and ROIV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KROS and ROIV compare
Roivant Sciences is the larger company, worth 140 times as much as Keros Therapeutics ($28.6B against $204M).
Roivant Sciences grew revenue faster over the last twelve months (102% versus −83.4% for Keros Therapeutics).
Keros Therapeutics keeps more of each dollar of sales as profit, with a net margin of −153% compared with −838% at Roivant Sciences.
Keros Therapeutics scores higher on the StockData Score (9 against 8 for Roivant Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KROS | ROIV |
|---|---|---|
| Size and price | ||
| Market cap | $204M | $28.6B |
| Share price | $10.30 | $39.53 |
| Change, 1 year | −41.0% | 85.4% |
| Change, 5 years | −82.8% | 394% |
| Beta (5Y) | 1.11 | 0.85 |
| Employees | 78 | 721 |
| StockData Score | ||
| Total score | 9 (better) | 8 |
| Valuation score | 3 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 1 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 5.1× (better) | 695× |
| P/B | 0.7× (better) | 7.1× |
| FCF yield | −23.6% | −0.12% (better) |
| Fair value | $24.09 | – |
| Margin of safety | 57.3% | – |
| Growth | ||
| Revenue growth (TTM) | −83.4% | 102% (better) |
| Revenue growth, 5Y average | – | −19.1% |
| Net income growth (TTM) | −196% | – |
| EPS growth (TTM) | −282% | – |
| Profitability | ||
| Operating margin | −181% (better) | −1358% |
| Net margin | −153% (better) | −838% |
| FCF margin | −119% | −81.2% (better) |
| Return on equity | −12.6% | −8.2% (better) |
| Return on invested capital | −389% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 18.14 (better) | 15.56 |
| Altman Z-score | 2.37 | 45.37 (better) |
| Piotroski F-score | 6 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 101% | 78.1% |
| Held by insiders | 53.3% | 13.9% |
| Insider net buying, 12 months | −$447K (better) | −$798M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 11.7% | 7.3% |
Go deeper
- KROS stock overview
- KROS income statement
- KROS valuation and score
- ROIV stock overview
- ROIV income statement
- ROIV valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.